Previous close | 1.5500 |
Open | 1.5500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.00 |
Expiry date | 2024-09-20 |
Day's range | 1.5500 - 1.5500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Here is how CareCloud, Inc. (CCLD) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.